Takeuchi K, Furukawa O, Tanaka H, Okabe S
Gastroenterology. 1986 Mar;90(3):636-45. doi: 10.1016/0016-5085(86)91118-2.
We standardized a new method for producing duodenal ulcers in rats by administering indomethacin plus histamine, and investigated the pathogenesis. Indomethacin (5 mg/kg) was first given subcutaneously to rats fasted for 24 h, and subsequently histamine dihydrochloride (40 mg/kg) was given subcutaneously three times, at 2.5-h intervals, beginning 30 min after injection of indomethacin. This combined treatment induced one or two round lesions (9.8 +/- 1.4 mm2) in the proximal duodenum at an incidence of 100%, and a few lesions in the corpus and antrum of the stomach as well. Indomethacin or histamine alone had no effect on either the duodenum or the stomach. The lesions in the duodenum and antrum were inhibited by oral cimetidine (3-100 mg/kg) and 16,16-dimethyl prostaglandin E2 (dmPGE2) (3-30 micrograms/kg) in a dose-related manner, whereas those in the corpus were inhibited only by cimetidine. Indomethacin alone had no effect on gastric acid secretion, but did potentiate the increase of acid secretion caused by histamine. Histamine did not affect duodenal HCO3-secretion, whereas indomethacin slightly inhibited the basal HCO3-secretion and completely blocked the acid-stimulated HCO3-secretion. Intraduodenally administered cimetidine (30 mg/kg) or dmPGE2 (30 micrograms/kg) significantly inhibited acid secretion or increased HCO3-secretion, respectively, and both reduced the amount of acid emptied into the duodenum after treatment with indomethacin plus histamine. These results indicate that the development of duodenal lesions induced by indomethacin plus histamine in rats is due to both an increase in gastric acid secretion and an impairment of acid-induced duodenal HCO3-secretion. This newly established model will be useful for studying the pathogenesis of duodenal ulcers and for screening antiulcer agents.
我们通过给予吲哚美辛加组胺,标准化了一种在大鼠中产生十二指肠溃疡的新方法,并研究了其发病机制。首先给禁食24小时的大鼠皮下注射吲哚美辛(5毫克/千克),随后在注射吲哚美辛30分钟后,每隔2.5小时皮下注射三次盐酸组胺(40毫克/千克)。这种联合治疗在十二指肠近端诱导出一个或两个圆形病变(9.8±1.4平方毫米),发生率为100%,胃体和胃窦也有一些病变。单独使用吲哚美辛或组胺对十二指肠或胃均无影响。十二指肠和胃窦的病变可被口服西咪替丁(3 - 100毫克/千克)和16,16 - 二甲基前列腺素E2(dmPGE2)(3 - 30微克/千克)以剂量相关的方式抑制,而胃体的病变仅被西咪替丁抑制。单独使用吲哚美辛对胃酸分泌无影响,但能增强组胺引起的胃酸分泌增加。组胺不影响十二指肠HCO3-分泌,而吲哚美辛轻微抑制基础HCO3-分泌并完全阻断酸刺激的HCO3-分泌。十二指肠内给予西咪替丁(30毫克/千克)或dmPGE2(30微克/千克)分别显著抑制胃酸分泌或增加HCO3-分泌,并且两者都减少了吲哚美辛加组胺治疗后排入十二指肠的酸量。这些结果表明,吲哚美辛加组胺在大鼠中诱导的十二指肠病变的发生是由于胃酸分泌增加和酸诱导的十二指肠HCO3-分泌受损。这个新建立的模型将有助于研究十二指肠溃疡的发病机制和筛选抗溃疡药物。